Discover the latest research with Meet the Trialist

Meet the Trialist is a series of virtual conversations discussing current discoveries and up-to-date data in clinical trials. These conversations take place from 4-4:45 p.m. on all five days of Scientific Sessions 2020.

Friday, Nov. 13
Session 1

  • Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: The Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) Trial
  • The Vital Rhythm Trial: Omega-3 Fatty Acid and Vitamin D Supplementation in the Primary Prevention of Atrial Fibrillation

Session 2

  • Aspirin Alone and in Combination With a Polypill in Cardiovascular Disease Primary Prevention: Results From the International Polycap Study (TIPS)-3
  • Prevalence and Prediction of Coronary Artery Disease in the General Population: Results From the Swedish Cardiopulmonary Bioimage Study (SCAPIS)

Saturday, Nov. 14
Session 3

  • Ticagrelor Versus Clopidogrel in Elective Percutaneous Coronary Intervention: The Alpheus Trial
  • Oral Anti-xa Anticoagulation After Trans-aortic Valve Implantation for Aortic Stenosis: The Randomized Atlantis Trial (Invited but not confirmed)

Sunday, Nov. 15
Session 4

  • STRENGTH Trial: Cardiovascular Outcomes With Omega-3-Carboxylic Acids in Patients With High Vascular Risk and Atherogenic Dyslipidemia
  • Effects of N-3 Fatty Acid Supplements on Clinical Outcome After Myocardial Infarction in the Elderly: Results of the OMEMI Trial

Session 5

  • A Three-arm N-of-1 Trial with Statin-, Placebo- and Tablet-Free Periods, to Verify Side Effects and Identify Their Cause: The SAMSON Trial
  • The Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia

Monday, Nov. 16
Session 6

  • Enhanced Monitoring for Atrial Fibrillation Following Cardiac Surgery: Primary Results of the SEARCH-AF Cardiolink Randomized Trial
  • Early Invasive Intervention for Atrial Fibrillation

Session 7

  • Rivaroxaban Versus Warfarin in Patients With Bioprosthetic Mitral Valves and Atrial Fibrillation or Flutter: Primary Results From the RIVER Randomized Trial
  • One-Month Dual Antipletelet Therapy Followed by Aspirin Monotherapy After Drug-Eluting Stent Implantation

Tuesday, Nov. 17
Session 8

  • Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
  • Ticagrelor Added to Aspirin in Acute Ischemic Stroke or TIA of Atherosclerotic Origin

Session 9

  • High Dose Versus Standard Dose Influenza Vaccine in Patients with High-Risk Cardiovascular Disease: Results From the Invested Trial
  • SCORED: Sotagliflozin in Patients With Diabetes and Chronic Kidney Disease